Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Pertuzumab and trastuzumab (SC, as PHESGO)","Breast cancer, HER2-positive, locally advanced, inflammatory or early-stage, neoadjuvant treatment","Pertuzumab and trastuzumab (SC, as PHESGO) (PHESGO)",Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
